5th & 6th September, London

**Confirmed 2023 Speakers** 

Lord James O'Shaughnessy, Member of the House of Lords, former Health Minister, Senior Partner at Newmarket
Strategy

Nigel Hughes, Scientific Director, Observational Health Data Analytics/Epidemiology, Johnson & Johnson, Office of the Chief Medical Officer

Dr Janet Messer, Director of Approvals Service, Health Research Authority (HRA)

Nigel Blackburn, Director of Drug Development, Cancer Research UK

lan Bruce, Director, NIHR Manchester Biomedical Research Centre

Emma Challans, Chair & Founder of PRroud2bOps and Director of Organisational Development, Culture and Talent NHS
Nottingham

Catherine Mela, Executive Director, Head of Biosamples, AstraZeneca

Prof Sandip Mitra, Deputy Director, NIHR Devices for Dignity MedTech Co-operative and Consultant Nephrologist & Professor of Renal Medicine, Manchester University NHS Foundation Trust

Sverre Bengtsson, Co-Founder, Senior Vice President Strategic Relations, Viedoc

James Rudge, Technical Director, Neoteryx

Roman Fishchuk, Head of Clinical Trials Department, Central City Clinical Hospital, Ukraine

Martin Edobor, Clinical Lead for Digital Transformation, NHS North East London

Romain Bejot, VP CMC & Supply, Blue Earth Diagnostics

Nina Skorytchenko, CEO, Avenna

Surbhi Gupta, Head of Regulatory Affairs, Thriva

Suki Balendra PhD, Director of Strategic Partnerships, Paddington Life Sciences. Life sciences Lead for the NIHR CRN North West London, Board Advisor

Marisa Papaluca, Expert medicines regulatory adviser. Former Senior Scientific Adviser, European Medicines Agency, and, Visiting Professor, Imperial College London

Oliver Buckley-Mellor, Research Policy Manager, The Association of the British Pharmaceutical Industry (ABPI)

Neelam Patel, CEO, MedCity

Erica White, Director of Innovation, Royal Free London NHS Foundation Trust

5TH-6TH SEPTEMBER | LONDON

Greig Duncan, Solution Sales Specialist - Clinical Operations, Medidata

Brian MacNamara, Senior Product Manager, Teckro

Krzysztof Potempa, Founder and Chief Executive Officer, Braincures

**Bob Stevens, Patient Advocate,** Group CEO, MPS Society & Rare Disease Research Partners Vice Chair, LSD Collaborative Co-Chair, **International MPS Network** 

Antoine Vigneau, Senior Director, Biosamples Head of Alliances and Technology, AstraZeneca

Becky Purvis, Director of Policy and Partnership, Health Research Authority (HRA)

#### Outsourcing in Clinical Trials UK and Ireland 2023

DAY 1 – 5 <sup>th</sup> September 2023		
8:00	Registration and refreshments	
8:50	Chairperson's opening remarks Emma Challans, Chair & Founder of Proud2bOps and Director of Organisational Development, Culture and Talent NHS Nottingham	
A	PANEL DISCUSSION	
	Building back a thriving, competitive life science sector in the UK & Ireland: the UK has fallen behind other countries in the number of studies initiated, with a drop of 44% in commercial clinical trials in the last five years taking us from 4th to 10th in the global standings.	
	Exploring maintenance and growth of research delivery in NHS sites	
	Appreciating global life science industry timelines; highlighting regulatory approval, ethics reviews, and the time it takes to set-up at a site, and recruit the first participants	
	Unlocking costing for commercial contract research	
9:00	<ul> <li>Addressing clinical capacity within the NHS in order to increase revenue and increase trials based in the UK</li> <li>Discussing MHRA Introductory measures to streamline the process of running trials making the UK a 'more attractive' place to</li> </ul>	
9:00	conduct clinical trials	
	Moderator: GlobalData	
	Panellists:	
	Ian Bruce, Director, NIHR Manchester Biomedical Research Centre	
	Oliver Buckley-Mellor, Research Policy Manager, The Association of the British Pharmaceutical Industry (ABPI)	
	Dr Janet Messer, Director of Approvals Service, Health Research Authority (HRA)	

Sales Enquiry

Ben Lloyd-Davies

Head of Sponsorship Sales
T: +44 (0)207 9472755
E: BenLloyd-Davies@arenainternational.com

Speaker Enquiry
Maya Hudson
Senior Conference
Producer
E: Maya.Hudson@arenainternational.com

Marketing Enquiry
Haida Amirzadah
Marketing Manager
E:

5TH-6TH SEPTEMBER | LONDON

9:30	Session Reserved for <b>Novotech</b>	
	Busting RBQM Myths: Practical Tools for Proactive Data Quality	Management in Clinical Trials
	It's time to bust the myths of managing data quality in today's complex clinical trials. The explosion of digital capabilities to collect and monitor data remotely is truly disrupting traditional paradigms and opening up opportunities to improve patient, sponsor, and site outcomes.	
10:00	However, as companies embrace digitalization, patient safety oversight and data reliability are the top concerns. Risk-based quality management (RBQM) strategies are increasingly used for decentralized trials to ensure data integrity and quality when various data types are collected and integrated from disparate sources. The industry still needs clarification about how best to implement these strategies in repeatable and scalable ways.	
	Join us as we "bust" five myths about data quality oversight and provide strategies to support the complexity of today's clinical trials.	de practical guidance on establishing effective clinical operations
Į.	Greig Duncan, Solution Sales Specialist - Clinical Operations, Medidata	
10:30	Morning refreshments and networking	
	STREAM A: Clinical Operations and Outsourcing	STREAM B: Clinical Technology and Innovation
	Chair: Emma Challans, Chair & Founder, Proud2bOps	Chair: <b>GlobalData</b>

Sales Enquiry

Ben Lloyd-Davies

Head of Sponsorship Sales

T: +44 (0)207 9472755

E: BenLloyd-Davies@arena-international.com

Speaker Enquiry
Maya Hudson
Senior Conference
Producer
E: Maya.Hudson@arenainternational.com

Marketing Enquiry **Haida Amirzadah**Marketing Manager

E:

mailto:Haida.Amirzadah@arena-

<u>international.com</u>

5TH-6TH SEPTEMBER | LONDON

11:00	<ul> <li>Diversity in Finding New Medicines</li> <li>Discussing how diversity affects medical research</li> <li>Focusing on the importance of diversity in health research</li> <li>Why is diversity needed in clinical trials for the advancement of medicine?</li> <li>Strategies for achieving IDEA (Inclusion, Diversity, Equity, and Access) in UK Clinical Trials</li> <li>Recognising steps the FDA have taken to address unrepresented minority groups in US clinical trials – can/should the UK expect to follow suit?</li> <li>Suki Balendra PhD, Director of Strategic Partnerships, Paddington Life Sciences. Life sciences Lead for the NIHR CRN North West London, Board Advisor</li> <li>Neelam Patel, CEO, MedCity</li> </ul>	The real-world data/experience paradigm shift & new architectures  • The emergence of federated data networks (FDNs) and trusted research environments (TREs) as a main architecture for evidence generation • The regulatory transition to FDNs in EU and UK - the role of EMA DARWIN EU(R) and MHRA strategy • Applications, e.g., pharmacovigilance and challenges e.g., governance  Nigel Hughes, Scientific Director, Observational Health Data Analytics/Epidemiology, Johnson & Johnson, Office of the Chief Medical Officer
11:30	'Spare a thought for the hospitals'  Davy Yeung, COO, TCRS	Session Reserved for <b>YPrime</b>

Sales Enquiry

Ben Lloyd-Davies

Head of Sponsorship Sales
T: +44 (0)207 9472755
E: BenLloyd-Davies@arenainternational.com

Speaker Enquiry
Maya Hudson
Senior Conference
Producer
E: Maya.Hudson@arenainternational.com

Marketing Enquiry
Haida Amirzadah
Marketing Manager
E:
mailto:Haida.Amirzadah@

5TH-6TH SEPTEMBER | LONDON

	Operational Management and Clinicians: Leaders change culture-culture changes organisations	How precision medicine technologies can be used as complementary diagnostics to optimise clinical trial efficiency
12:00	In this session we will take the opportunity to reflect and learn from the lived experiences of our speaker, supported by tangible examples of culture transformation and organisational effectiveness. In exploring this, we will together consider the role of operational managers, and clinical leaders in influencing culture, leading by the shoulder of others and how through shared vision and values you can help improve the effectiveness of an organisation.  Our aim is for you to learn, be curious and leave with energy and practical tips to help you lead well, approach change with confidence and recognise the value of collaborative leadership in challenging times.  Emma Challans, Chair & Founder of PRroud2bOps and Director of Organisational Development, Culture and Talent NHS Nottingham	<ul> <li>Improving success rates of clinical trials for anti-inflammatory drugs using prognostic and predictive biomarkers for chronic inflammatory diseases (cIDs)</li> <li>Overview current and next generation biomarkers for Inflammatory Bowel Disease (IBD)</li> <li>GlyHealth technology– Glycomics as a Sweet Spot in Precision Medicine diagnostics</li> <li>Addressing challenges in anti-Inflammatory drug development with GlyHealth biomarkers (stronger evidence, better selection and higher approval rates for drugs)</li> <li>Optimising clinical trial efficiency with reliable, precision medicine biomarkers for Chronic Inflammatory Diseases (cIDs)</li> <li>Nina Skorytchenko, CEO, Avenna</li> </ul>
6		Hybrid trials using DCT technology and processes; focus on patients and the sites
Y	Implementation Science in biomedical research	<ul> <li>Highlighting the complexity that Hybrid/DCT brings whilst moving away from the common brick-and-mortar sites.</li> <li>Discussing the rise in regulator concerns in areas such as investigator oversight, and participant's safety when face to face contact is limited.</li> <li>How we tend to focus too much on technology when it's actually the processes for the patients and the sites that</li> </ul>
12:30	Angela Ibald, Real World Evidence leader Emmes	<ul> <li>matter even more.</li> <li>Major points to consider in designing hybrid/DCT trials; building blocks and practical examples to best prepare you to meet the needs of regulators whilst keeping the patient and sites front of mind.</li> </ul>
		and sites from or mind.
		Sverre Bengtsson, Co-Founder, Senior Vice President Strategic Relations, Viedoc

Sales Enquiry

Ben Lloyd-Davies

Head of Sponsorship Sales
T: +44 (0)207 9472755
E: BenLloyd-Davies@arenainternational.com

Speaker Enquiry
Maya Hudson
Senior Conference
Producer
E: Maya.Hudson@arenainternational.com

Marketing Enquiry
Haida Amirzadah
Marketing Manager
E:

5TH-6TH SEPTEMBER | LONDON

#### **Delivering trials through NHS Organisations** INTERACTIVE SESSION This workshop will explore different approaches and strategies As Research Lead for the NHS Trust Manchester Royal Infirmary at for putting patients at the centre when collecting samples for Manchester University Hospitals, one of the largest NHS hospital decentralised and hybrid clinical trials trusts in UK, Professor Sandip Mitra has been involved in delivering research trials for 15+ yrs working in partnership with industry and Primer on costs of centralised trials and how decentralisation helps to reduce costs and drive external stakeholders. He understands the growing need to interact recruitment with commercial organisations and research platforms and how to successfully engage with NHS systems and clinical teams to deliver Discuss benefits of decentralised clinical trials 14:00 Discuss challenges research What does the future look like? This session will cover the following: Navigating through NHS systems and pathways for efficient delivery of R&I trials James Rudge, Technical Director, Neoteryx Professor Sandip Mitra, Deputy Director, NIHR MedTech Cooperative D4D, Consultant Nephrologist & Professor of Medicine, Manchester University Hospitals NHS Foundation Trust Running Up That Hill: Accelerate Cycle Times & Reach Patients Faster with elluminate This presentation will highlight how the elluminate Clinical Data Cloud and Biometrics Services can reshape your data architecture by automating data flows to keep up with the pace of data evolution and speed time to insights. Learn how elluminate and eClinical's Biometrics Services deliver: Operational insights across numerous data sources that provides definitive answers and analytics on enrollment, protocol compliance and safety Improved study oversight with a holistic view of risk across all data sources 50 out-of-the-box visualizations to support cross-study Session Reserved for Calyx 14:30 analysis for deeper insights with self-service access to clinical and operational analytics Increased productivity across data management, medical monitoring, clinical operations, clinical programming and statistical analysis roles eClinical Solutions Featured toolkit coverage: Capturing a representative and equitable sample in health research Research participants often do not represent the target population for treatment, limiting generalisability of research findings and perpetuating health inequalities

Sales Enquiry

Ben Lloyd-Davies

Head of Sponsorship Sales

T: +44 (0)207 9472755

E: BenLloyd-Davies@arena-international.com

Speaker Enquiry
Maya Hudson
Senior Conference
Producer
F: Maya Hudson@at

E: Maya.Hudson@arenainternational.com Marketing Enquiry
Haida Amirzadah
Marketing Manager

5TH-6TH SEPTEMBER | LONDON

		<ul> <li>The Toolkit addresses this by providing guidance to inform representative and equitable inclusion in research</li> <li>Use of the Toolkit may promote trust between communities and research institutions, increase participation in, and improve generalisability of health research</li> <li>Ameeta Retzer, Equity, Diversity and Inclusion Lead, National Institute of Health and Care Research Applied Research Collaboration West Midlands</li> </ul>
W.	PANEL DISCUSSION	PANEL DISCUSSION
	What are the different outsourcing relationships and how do you manage them?	Focusing on today's Innovation & Technological Advancements
	<ul> <li>What are the categories and the driving needs for 2023?</li> <li>How has this changed over the years?</li> <li>Key strategies that sponsor companies have – how has this changed?</li> <li>Did the pandemic effect these strategies?</li> </ul>	<ul> <li>Are we making the most of Technology &amp; Innovation in the UK Clinical Trial space?</li> <li>How are these tools being utilised?</li> <li>What's next?</li> <li>Considering the use of AI in healthcare &amp; Clinical Trials</li> </ul>
:00	Moderator: Emma Challans, Chair & Founder, Proud2bOps  Panelists:	Moderator: Erica White, Director of Innovation, Royal Free London NHS Foundation Trust
	John McEvoy, General Counsel, Amryt Pharma	Panelists:
	Diane Driver, Head Program Delivery, PV Development Solutions, UCB BioPharma UK	Krzysztof Potempa, Founder and Chief Executive Officer, Braincures
	Nicola Yallup, Head of Business Development and Marketing,	Martin Edobor, Clinical Lead for Digital Transformation, NHS North East London
	NIHR Clinical Research Network	Marisa Papaluca, Expert medicines regulatory adviser. Former Senior Scientific Adviser, European Medicines Agency and, Visiting Professor, Imperial College London
- 2	A	4 17 SOME THE PROPERTY AND ADDRESS.
	Afternoon refreshments and networking	

Sales Enquiry

Ben Lloyd-Davies

Head of Sponsorship Sales
T: +44 (0)207 9472755
E: BenLloyd-Davies@arenainternational.com

Speaker Enquiry
Maya Hudson
Senior Conference
Producer
E: Maya.Hudson@are

E: Maya.Hudson@arenainternational.com Marketing Enquiry
Haida Amirzadah
Marketing Manager
E:

5TH-6TH SEPTEMBER | LONDON

Clos	sion Reserved for Event Sponsor  Sing Keynote
(CO) (111)	osing Keynote
(CO) (111)	osing Keynote
CZ305 ( 101) 3	
The	Patients Perspective
Help	ping patients on their clinical trial journey
16:30	Living with a rare disease
	<ul> <li>Patient expectations &amp; considerations</li> <li>Proven approaches to increase patient retention in clinical trials</li> </ul>
13 13	Focusing on the future of patients in clinical trials  OF ALTO ALTO ALTO ALTO ALTO ALTO ALTO ALTO
	Stevens, Patient Advocate, Group CEO, MPS Society & Rare Disease Research Partners Vice Chair, LSD Collaborative Co-Chair, rnational MPS Network

#### **END OF DAY 1 AND NETWORKING DRINKS RECEPTION SPONSORED BY TFS**

# Outsourcing in Clinical Trials UK and Ireland 2023 DAY 2 – 6<sup>th</sup> September 2023 8:00 Registration and refreshments Chairperson's opening remarks Chair: Barbara Hepworth-Jones, Director Capability Building, Global Clinical Operations, GSK

Sales Enquiry

Ben Lloyd-Davies

Head of Sponsorship Sales
T: +44 (0)207 9472755
E: BenLloyd-Davies@arenainternational.com

Speaker Enquiry
Maya Hudson
Senior Conference
Producer
E: Maya.Hudson@arenainternational.com

Marketing Enquiry
Haida Amirzadah
Marketing Manager
E:
mailto:Haida.Amirzadah@arenainternational.com

5TH-6TH SEPTEMBER | LONDON

	OPENING KEYNOTE: CLINICAL TRIAL REVIEW
9:00	The government have appointed Lord James O'Shaughnessy to conduct an independent review into the UK commercial clinical trials landscape. This review will offer recommendations on how commercial clinical trials can help the life sciences sector unlock UK growth and investment opportunities. It will also advise on how to resolve key challenges in conducting commercial clinical trials in the UK.
	Lord James O'Shaughnessy, Member of the House of Lords, former Health Minister, Senior Partner at Newmarket Strategy
678	Accelerated performance of complex exploratory patient studies: practical insights from investigational site
9:30	<ul> <li>Unique model of dedicated research clinics in Eastern Europe</li> <li>Strategies for fast patient enrollment and retention</li> <li>Operational tips for flawless study conduct</li> <li>Takeaways after operating under unprecedented circumstances / case studies</li> </ul>
	Dr. Claudia Hesselmann, Founder and CEO, Arensia
10:00	How NIHR infrastructure can enhance industry and commercial collaboration in clinical trials: the Greater Manchester Example
	<ul> <li>Outline of current NIHR Infrastructure</li> <li>How NIHR infrastructure can support industry collaborations</li> <li>Post Covid RESET and research recovery</li> </ul>
	lan Bruce, Director, NIHR Manchester Biomedical Research Centre
	Rethinking Sponsor Oversight in a Digital First World
	The transition from a manual, paper-based approach to a digital first approach in clinical trials opens new opportunities for sponsors to achieve enhanced oversight on study progress, quality, and patient safety. This session will address how data insights generated from digital first clinical trials:
	Increase speed and transparency
10:30	Redefine site engagement
	Identify areas for corrective action sooner
	Generate learning capital for other trials
	Brian MacNamara, Senior Product Manager, Teckro

Sales Enquiry **Ben Lloyd-Davies**Head of Sponsorship Sales
T: +44 (0)207 9472755

E: BenLloyd-Davies@arena-international.com

Speaker Enquiry
Maya Hudson
Senior Conference
Producer
E: Maya.Hudson@arenainternational.com

Marketing Enquiry Haida Amirzadah Marketing Manager E:

5TH-6TH SEPTEMBER | LONDON

	STREAM A: Clinical Operations and Outsourcing Chair: Barbara Hepworth-Jones, Director Capability Building, Global Clinical Operations, GSK	STREAM B: Clinical Technology and Innovation
A	Protecting Our Planet: Minimising carbon impact in Human Biosample lifecycle in clinical trials	Regulatory considerations for Remote Diagnostics in Decentralised clinical trials
11:30	<ul> <li>Focusing on the minimization of our carbon footprint of Human samples in clinical trials</li> <li>Finding the balance between scientific impact &amp; the cost to our planet</li> <li>Small changes can have a large impact - cold chain</li> <li>Catherine Mela, Executive Director, Head of Biosamples, AstraZeneca</li> </ul>	<ul> <li>The session will discuss Regulatory Considerations to avoid pitfalls later down the line focussing on following key areas</li> <li>Regulatory Approval including application submission to regulatory bodies such as the MHRA</li> <li>Informed Consent: to ensure participants understand the nature of the remote testing procedures and the risks and benefits involved</li> <li>Data Security and Privacy: remote diagnostic testing involves the transmission of sensitive health information over digital platforms. Appropriate measures to protect the privacy and security of participant data will be discussed.</li> <li>Quality Assurance: to ensure that the data collected is accurate and reliable Remote diagnostic testing can offer several advantages in decentralized clinical trials, including increased convenience and reduced participant burden. However, it is essential to ensure that appropriate regulatory considerations are taken into account to ensure the safety and integrity of the study data.</li> <li>Surbhi Gupta, Head of Regulatory Affairs, Thriva</li> </ul>
12:00	Session Reserved for <b>Merative</b>	Session Reserved for <b>EMIS</b>

Sales Enquiry

Ben Lloyd-Davies

Head of Sponsorship Sales
T: +44 (0)207 9472755
E: BenLloyd-Davies@arenainternational.com

Speaker Enquiry
Maya Hudson
Senior Conference
Producer
E: Maya.Hudson@arenainternational.com

Marketing Enquiry
Haida Amirzadah
Marketing Manager
E:
mailto:Haida.Amirzadah@arenainternational.com

5TH-6TH SEPTEMBER | LONDON

12:30	Lunch and networking	
-	Fireside Chat	Data to Drive Sustainability
	Reviewing shifts in the UK clinical trial space and thoughts on where we go from here.	Collecting and using data to make decisions that guide measurable and responsible clinical practices
13:30	This talk will include an overview on the huge decision for Cancer Research UK to consider taking their trials outside of the UK for the first time ever.  Moderator: Barbara Hepworth-Jones, Director Capability Building, Global Clinical Operations, GSK  Nigel Blackburn, Director of Drug Development, Cancer Research UK	<ul> <li>What is sustainability data collection?</li> <li>Discussing how data is useful for sustainable development</li> <li>Focusing on how to manage sustainability data</li> </ul> Antoine Vigneau, Senior Director, Biosamples Head of Alliances and Technology, AstraZeneca
14:00	Challenges of just in-time manufacturing and supply of investigational products (perspectives from experience with short-lived radiopharmaceuticals)  Overview of the supply chain: e.g., manufacture, release, importation  Specificities of local vs. centralised production, incl. redundancy/performance aspects and management of multiple CDMOs/vendors  IRT and IMP order/accountability  practical experience with US/Europe clinical trials  specific challenges with clinical trials in the UK (manufacture, Northern Ireland status, importation, release)  Romain Bejot, VP CMC & Supply, Blue Earth Diagnostics	Decentralised and people-centric trials; how and why this approach could make it easier to run trials in the UK - including sharing details of the national survey the HRA recently conducted with the public to understand the views of patient and the public about participating in research  Understand what builds public trust in research Explore actions you can take to make research more people-centred  Learn how you can implement people-centric and decentralised research in the UK  Dr Janet Messer, Director of Approvals Service, Health Research Authority (HRA)
14:30	KEYNOTE FROM THE MHRA: An overview of the MHRA's consults     An overview of proposals for the UK's clinical trial legislation safe and innovative medicines     Results from the MHRA's consultation: feedback on propose     What the new clinical trial legislation will mean for the future.	n designed to make the UK the best place to research and develop
	Tentative confirmation – MHRA Senior representative	
15:15	Afternoon refreshments, networking, and Apple Prize Draw	

Ben Lloyd-Davies
Head of Sponsorship Sales
T: +44 (0)207 9472755
E: BenLloyd-Davies@arenainternational.com

Speaker Enquiry
Maya Hudson
Senior Conference
Producer
E: Maya.Hudson@arenainternational.com

Haida Amirzadah Marketing Manager E:

5TH-6TH SEPTEMBER | LONDON

	PROBLEM-SOLVING ROUNDTABLE DISCUSSIONS  During the roundtable discussion session, the conference hall will be divided into two 'zones'. Delegates can choose which zone they would like to join. Each zone will be led by a table moderator and will focus on a different challenge within clinical operations in oncology trials. After 30 minutes, delegates will have the opportunity to swap and choose a different table, and each roundtable will run twice.	
	RT 1- Disaster Preparedness: How can the clinical trial industry prepare for the unexpected? Using the Ukrainian crisis as central to the conversation	
	Roman Fishchuk, Head of Clinical Trials Department, Central City Clinical Hospital, Ukraine	
15:45	RT 2- How do you successfully adopt and scale proven research & innovation across the health and care sector.  Erica White, Director of Innovation, Royal Free London NHS Foundation Trust	
The same	RT 3 Responsible AI in Healthcare & Clinical Trials – how industry and the NHS can work together  Katie Tucker, Senior Innovation Consultant, Royal Free London NHS Foundation Trust	
	RT 4- Strategies for achieving IDEA (Inclusion, Diversity, Equity, and Access) in UK Clinical Trials – where do we go from here? Recommendations on how to move forward.	
V	Suki Balendra PhD, Director of Strategic Partnerships, Paddington Life Sciences. Life sciences Lead for the NIHR CRN North West London, Board Advisor	
	RT 5 Paradigm shift: The power of partnership working	
	Nicola Yallup, Head of Business Development and Marketing, NIHR Clinical Research Network	
	RT 6 Making it easier to do clinical trials that everyone can trust: making research more transparent and increasing public involvement in a proportionate and agile way. Supporting best practice for all studies.	
	Becky Purvis, Director of Policy and Partnership, Health Research Authority (HRA)	
16:45	Chairperson's closing remarks Barbara Hepworth-Jones, Director Capability Building, Global Clinical Operations, GSK	

#### **END OF CONFERENCE**

Sales Enquiry

Ben Lloyd-Davies

Head of Sponsorship Sales

T: +44 (0)207 9472755

E: BenLloyd-Davies@arena-international.com

Speaker Enquiry
Maya Hudson
Senior Conference
Producer
E: Maya.Hudson@arenainternational.com

Marketing Enquiry
Haida Amirzadah
Marketing Manager
E:
mailto:Haida Amirzadah